Select country set
Menu Shopping cart 0,00 Search
Distributed product

Nanopia KL-6 Reagent 1

  • Regulatory status:RUO
  • Type:Immunoturbidimetric assay
  • Other names:Sialylated Carbohydrate Antigen, Krebs von den Lungen-6, Mucin-1, MUC-1, Breast carcinoma-associated antigen DF3, Cancer antigen 15-3, CA 15-3, Carcinoma-associated mucin, Episialin, H23AG, Krebs von den Lungen-6, PEMT, Peanut-reactive urinary mucin, PUM, Polymorphic epithelial mucin, PEM, Tumor-associated epithelial membrane antigen, EMA, Tumor-associated mucin, CD227
  • Species:Multispecies
Please select your region to see available products and prices.
Cat. No. Size Price

New 466175 320 tests (2 X 24 mL)
PubMed Product Details
Technical Data


Immunoturbidimetric assay


Serum, Plasma, COVID-19


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box). Do not freeze.

Calibration Range

105.3 - 401.2 U/mL

Dilution Linearity

50-5000 U/mL


Research topic

Immune Response, Infection and Inflammation, Oncology, Pulmonary diseases, COVID-19


KL-6 is a sialylated carbohydrate antigen that was detected by Kohno et al. in 1985. It is a high molecular weight glycoprotein that is expressed by type II alveolar epithelial cells and is a mucin which belongs to MUC-1 in cluster 9.1,2 ,4 It has been confirmed that the serum KL-6 level is significantly higher in subjects with interstitial pneumonia than in healthy volunteers or subjects with other respiratory diseases, and it has been shown by ROC analysis that serum KL-6 is a diagnostically useful indicator.3 In addition, because serum KL-6 Levels are significantly higher in subjects with active interstitial pneumonia than in subjects with inactive pneumonia, serum KL-6 is considered to be useful for assessing disease activity. Furthermore, it has been noted that this parameter changes according to the pathology of interstitial pneumonia during follow-up.3

Product References (2)


  • Bonella F, Long X, Ohshimo S, Horimasu Y, Griese M, Guzman J, Kohno N, Costabel U. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2016 Apr 23;11:48. doi: 10.1186/s13023-016-0430-2. PubMed PMID: 27108412. PubMed CentralPMCID: PMC4841967. See more on PubMed
  • Horie T, Mizuma T, Kasai S, Awazu S. Conformational change in plasma albumin due to interaction with isolated rat hepatocyte. Am J Physiol. 1988 Apr;254(4 Pt 1):G465-70. doi: 10.1152/ajpgi.1988.254.4.G465. PubMed PMID: 2833115. See more on PubMed
Summary References (15)

References to KL-6

  • Arase Y, Ikeda K, Suzuki Y, Kobayashi M, Suzuki F, Akuta N, Sezaki H, Hosaka T, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. Intern Med. 2007;46 (15):1155-60
  • Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, Soh J, Tanimoto Y, Kanehiro A, Kato K, Date H, Tanimoto M. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer. 2008 Jan;59 (1):81-7
  • Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest. 1992 Mar;101 (3):858-60
  • Kida Y, Maeshima E, Furukawa K, Ichikawa T, Goda M, Ichinose M. A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol. 2007;17 (3):262-4
  • Kikuchi N, Ishii Y, Ohtsuka M. Serum KL-6 levels and acute lung inflammation. Intern Med. 2007;46 (6):335; author reply 337
  • Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995 Aug;108 (2):311-5
  • Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest. 1996 May;109 (5):1276-82
  • Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988 Sep;18 (3):203-16
  • Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, Yokoyama A, Hamada H, Fujioka S, Hiwada K. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993 Sep;148 (3):637-42
  • Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest. 1992 Jul;102 (1):117-22
  • Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989 Jul;96 (1):68-73
  • Kohno N, Kyoizumi S, Tanabe M, Oyama T, Vossler M, Yamakido M, Akiyama M. Detection of a circulating tumor-associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. Cancer Res. 1989 Jun 15;49 (12):3412-9
  • Kunitake R, Kuwano K, Yoshida K, Maeyama T, Kawasaki M, Hagimoto N, Hara N. KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Respiration. 2001;68 (5):488-95
  • Ohtsuki Y, Nakanishi N, Fujita J, Yoshinouchi T, Kobayashi M, Ueda N, Lee GH, Furihata M. Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. Med Mol Morphol. 2007 Sep;40 (3):163-7
  • Tang W, Guo Q, Qu X, Inagaki Y, Seyama Y, Midorikawa Y, Gai R, Kokudo N, Sugawara Y, Nakata M, Makuuchi M. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma. Oncol Rep. 2007 Apr;17 (4):737-41
Related Products Docs